currently has three other distinct series of LSAIDs from its
Inflazyme has other LSAIDs in clinical and pre-clinical development for other inflammatory diseases that are not included in the Aventis partnership.
An orally active LSAID, IPL550,260, is completing Phase I clinical trials.
In addition to its LSAID programs, Inflazyme also has phosphodiesterase inhibitor programs directed towards memory disorders and inflammatory diseases.
Further novel LSAIDs, from different chemical series are also under development.
A further orally active LSAID, IPL550,260, is completing Phase I clinical trials.
As well as its PDE4 inhibitor program, Inflazyme's other technologies are novel, orally active, LSAIDs (Leukocyte Selective Anti-Inflammatory Drugs).
In addition to the expansion of the collaboration around IPL512,602, we have also agreed to work with Aventis on the development of another respiratory compound from a new series of LSAIDs, the IPL12 series.
The decision by Aventis' to take over the costs for IPL 512,602 will reduce our cash burn which significantly increases our flexibility to direct resources to the development of our LSAIDs for other, non-respiratory, indications with other potential partners.